Quarterly report · Q2
4544.TEDINET S100S6Z0
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥116.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥260.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥134.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | −¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥17.7bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | −¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥22.0bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.8bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥20.7bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥15.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥15.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥1.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥15.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥284.6bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥297.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥287.2bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥134.4bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥147.9bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥150.1bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥150.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥157.2bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥37.1bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥44.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥37.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥44.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥37.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥5.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥32.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥15.8bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥7.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥29.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥18.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥6.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥7.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-32 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-12.33 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥275.52 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥273.87 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥175.63 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥275.5 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥273.84 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 52.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.3% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.7% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥3.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥3.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥2.8bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥72.4bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥72.3bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥74m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥6.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥33.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥30.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥14.0bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥14.0bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3m |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥564m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥119.6bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥116.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3.1bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥5.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥5.1bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥1.5bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥85.1bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥85.0bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥83m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.9bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥40.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥35.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.0bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥15.7bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥10m |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥604m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥139.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥134.1bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.1bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥19.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 524
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 11140600 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.1947 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 3812900 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.0666 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 2379900 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0416 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 1948600 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0341 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 1680300 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0294 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 1538600 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0269 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 1272300 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0222 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 1272200 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0222 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 1000400 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0175 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 976500 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0171 | |
| Number of shares held | CurrentQuarterInstant | 27022400 | |
| Shareholding ratio | CurrentQuarterInstant | 0.4723 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 261600 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 57092800 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 570928 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 119422 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 57473822 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 570928 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 261600 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 261600 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0046 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 261600 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 261600 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0046 | |
| Cash and deposits | Prior1YearInstant | 44186000000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 37097000000 | JPY |
| Notes and accounts receivable trade and contract assets | Prior1YearInstant | 46946000000 | JPY |
| Notes and accounts receivable trade and contract assets | CurrentQuarterInstant | 48455000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 6469000000 | JPY |
| Merchandise and finished goods | CurrentQuarterInstant | 6216000000 | JPY |
| Work in process | Prior1YearInstant | 7072000000 | JPY |
| Work in process | CurrentQuarterInstant | 7842000000 | JPY |
| Raw materials and supplies | Prior1YearInstant | 8587000000 | JPY |
| Raw materials and supplies | CurrentQuarterInstant | 8520000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |